Gemstone Biotherapeutics develops a biosynthetic scaffold technology for advanced wound healing, targeting chronic and acute wounds. The company plans to use new capital for further testing, regulatory submittals and initial clinical trials. It completed a $1.6M second funding round led by founding investor Gamma 3 LLC with participation from an international healthcare fund. The financing brings Gemstone's total capital raised to $2.45M. Founded in 2013 and based in Baltimore, the company was formed around technology developed by Dr. Sharon Gerecht and licensed from Johns Hopkins University. Gemstone holds a patent portfolio covering cell-engineering methods and biomaterials to promote vascularization and is led by CEO George Davis.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2015